Skip to main content
Top
Published in: Rheumatology International 7/2013

01-07-2013 | Original Article

IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents

Authors: Valderilio Feijó Azevedo, J. R. Faria-Neto, Andrea Stinghen, Pedro G. Lorencetti, Wagner P. Miller, Beatriz P. Gonçalves, Carla C. Szyhta, Roberto Pecoits-Filho

Published in: Rheumatology International | Issue 7/2013

Login to get access

Abstract

The objective of the study was to investigate the association between IL-8 and other biomarkers of endothelial dysfunction (MCP-1, V-CAM, I-CAM) and the disease activity scores in a sample of 54 patients with ankylosing spondylitis (AS) without use of biological agents. Fifty-four AS patients without treatment with anti-TNFs agents between 18 and 80 years old, who met modified New York criteria and at the same time the axial ASAS criteria, were evaluated using an epidemiological questionnaire that included among others clinical data, BASDAI, BASFI, ASQoL, ASDAS and plasma levels of CRP, ESR, MCP-1, IL-8, ICAM-1 and VCAM-1. IL-8 varied in proportion to disease activity rates (BASDAI and ASDAS) p < 0.05, being strongly correlated with the disease activity. The levels of adhesion molecules I-CAM and VCAM, as described in other studies, were positively correlated with predisposing factors for cardiovascular disease. IL-8 has shown to be strongly correlated with clinical markers of disease activity and inflammatory activity and may be an additional variable to the overall assessment of the activity of the AS.
Literature
1.
2.
go back to reference Van Der Linden S, Van Der Heijde D (1998) Ankylosing spondylitis: clinical features. Rheum Dis Clin North Am 24(4):663–676PubMedCrossRef Van Der Linden S, Van Der Heijde D (1998) Ankylosing spondylitis: clinical features. Rheum Dis Clin North Am 24(4):663–676PubMedCrossRef
3.
go back to reference Sampaio-Barros P, Azevedo VF, Bonfiglioli R, Campos WR, Carneiro SCS, Carvalho MAP et al (2007) Consenso brasileiro de espondiloartropatias: espondilite anquilosante e artrite psoriásica diagnóstico e tratamento—primeira revisão. Rev Bras Reumatol 47(4):233–242CrossRef Sampaio-Barros P, Azevedo VF, Bonfiglioli R, Campos WR, Carneiro SCS, Carvalho MAP et al (2007) Consenso brasileiro de espondiloartropatias: espondilite anquilosante e artrite psoriásica diagnóstico e tratamento—primeira revisão. Rev Bras Reumatol 47(4):233–242CrossRef
4.
go back to reference Peters MJ, van der Horst-Bruinsma IE et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592PubMedCrossRef Peters MJ, van der Horst-Bruinsma IE et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592PubMedCrossRef
5.
go back to reference Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed
6.
go back to reference Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 8(4):437–449PubMedCrossRef Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 8(4):437–449PubMedCrossRef
7.
go back to reference Onat A, Direskeneli H (2012) Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 18(11):1465–1477PubMedCrossRef Onat A, Direskeneli H (2012) Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 18(11):1465–1477PubMedCrossRef
8.
go back to reference Kang JH, Chen YH, Lin HC (2010) Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 69(6):1165–1168 (Epub 2010 Apr 7)PubMedCrossRef Kang JH, Chen YH, Lin HC (2010) Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 69(6):1165–1168 (Epub 2010 Apr 7)PubMedCrossRef
9.
go back to reference Joven J, Rubiés-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoprotein cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 27(10):1199–1200PubMedCrossRef Joven J, Rubiés-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoprotein cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 27(10):1199–1200PubMedCrossRef
10.
go back to reference Azevedo VF, Pecoits-Filho R (2010) Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 30(11):1411–1416PubMedCrossRef Azevedo VF, Pecoits-Filho R (2010) Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 30(11):1411–1416PubMedCrossRef
11.
go back to reference Wright HL, Moots RJ, Bucknall RC, Edwards SW (2010) Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49(9):1618–1631 (Epub 2010 Mar 24)CrossRef Wright HL, Moots RJ, Bucknall RC, Edwards SW (2010) Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49(9):1618–1631 (Epub 2010 Mar 24)CrossRef
12.
go back to reference Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD (2011) Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 31(2):153–164PubMedCrossRef Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD (2011) Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 31(2):153–164PubMedCrossRef
13.
go back to reference Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH (2004) Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol 16(1):18–24PubMedCrossRef Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH (2004) Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol 16(1):18–24PubMedCrossRef
14.
go back to reference Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75PubMedCrossRef Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75PubMedCrossRef
15.
go back to reference Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL, Feuerstein GZ (1994) Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 75(1):1–7 Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL, Feuerstein GZ (1994) Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 75(1):1–7
16.
go back to reference Apostolakis S, Papadakis EG, Krambovitis E, Spandidos DA (2006) Chemokines in vascular pathology. Int J Mol Med 17:691–701PubMed Apostolakis S, Papadakis EG, Krambovitis E, Spandidos DA (2006) Chemokines in vascular pathology. Int J Mol Med 17:691–701PubMed
17.
go back to reference Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307(1):97–101PubMedCrossRef Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307(1):97–101PubMedCrossRef
18.
go back to reference Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA et al (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718–723PubMedCrossRef Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA et al (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718–723PubMedCrossRef
19.
go back to reference Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL et al (1994) Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 75:1–7PubMedCrossRef Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL et al (1994) Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 75:1–7PubMedCrossRef
20.
go back to reference O’Hayre M, Salanga CL, Handel TM, Allen SJ (2008) Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409:635–649PubMedCrossRef O’Hayre M, Salanga CL, Handel TM, Allen SJ (2008) Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409:635–649PubMedCrossRef
21.
go back to reference Conti P, DiGioacchino M (2001) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22:133–137PubMedCrossRef Conti P, DiGioacchino M (2001) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22:133–137PubMedCrossRef
22.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedCrossRef
23.
go back to reference Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J (2009) The development of Assessment of Spondylarthritis international Society classification criteria for axial spondylarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783 (Epub 2009 Mar 17)PubMedCrossRef Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J (2009) The development of Assessment of Spondylarthritis international Society classification criteria for axial spondylarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783 (Epub 2009 Mar 17)PubMedCrossRef
24.
go back to reference Taylor PC, PetersAM Paleolog E, ChapmanPT Elliott MJ, McCloskey R et al (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthrit Rheum 43:38–47CrossRef Taylor PC, PetersAM Paleolog E, ChapmanPT Elliott MJ, McCloskey R et al (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthrit Rheum 43:38–47CrossRef
25.
go back to reference Limón-Camacho L, Vargas-Rojas MI, Vázquez-Mellado J, Casasola-Vargas J, Moctezuma JF, Burgos-Vargas R, Llorente L (2012) In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol 39(4):830–835 Limón-Camacho L, Vargas-Rojas MI, Vázquez-Mellado J, Casasola-Vargas J, Moctezuma JF, Burgos-Vargas R, Llorente L (2012) In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol 39(4):830–835
26.
go back to reference Azuz-Lieberman N et al (2005) The involvement of NK cells in ankylosing spondylitis. Int Immunol 17(7):837–845PubMedCrossRef Azuz-Lieberman N et al (2005) The involvement of NK cells in ankylosing spondylitis. Int Immunol 17(7):837–845PubMedCrossRef
27.
go back to reference Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation 96:4219–4225PubMedCrossRef Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation 96:4219–4225PubMedCrossRef
28.
go back to reference Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L et al (2001) Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358:971–976PubMedCrossRef Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L et al (2001) Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358:971–976PubMedCrossRef
29.
go back to reference Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Leor J, Mekori YA et al (2002) Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the bezafibrate infarction prevention (BIP) Study. J Am Coll Cardiol 39:1133–1138PubMedCrossRef Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Leor J, Mekori YA et al (2002) Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the bezafibrate infarction prevention (BIP) Study. J Am Coll Cardiol 39:1133–1138PubMedCrossRef
Metadata
Title
IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents
Authors
Valderilio Feijó Azevedo
J. R. Faria-Neto
Andrea Stinghen
Pedro G. Lorencetti
Wagner P. Miller
Beatriz P. Gonçalves
Carla C. Szyhta
Roberto Pecoits-Filho
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2631-x

Other articles of this Issue 7/2013

Rheumatology International 7/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.